relapsing


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to relapsing: relapsing fever

re·lap·sing

(rē-lap'sing),
Recurring; said of a disease or its manifestations that returns in a new attack after an interval of improvement.

relapsing

/re·laps·ing/ (rĕ-lap´sing) (re´lap-sing) recurrent; denoting an illness that is characterized by periods of remission alternating with attacks of symptomatic disease.

relapsing

Etymology: L, relabi, to slide back
pertaining to the return of disease after a period of apparent recovery.

re·lap·sing

(rē-lap'sing)
Recurring; said of a disease or its manifestations that recurs after an interval of improvement.
References in periodicals archive ?
Whether we are likely to see the reemergence of this disease is difficult to predict because we do not understand relapsing fever borreliae and their complex host interactions.
Compatible clinical disease descriptions have been documented since the time of Hippocrates; however, the term relapsing fever was first used by David Craigie to describe an outbreak of the disease in Edinburgh in 1843 (1).
AVONEX is the world's leading treatment for relapsing forms of multiple sclerosis.
Tick-borne relapsing fever caused by Borrelia hermsii, Montana.
Obtaining cultures or performing histochemical staining can help rule out infectious organisms, while clinical tests for cartilage matrix proteins or antibodies to type II collagen (found uniquely in cartilage) can help define relapsing polychondritis.
A relapsing fever group spirochete transmitted by Ixodes scapularis ticks.
There are two general forms of relapsing fever, epidemic (louse borne--Pediculus humanus) and endemic (tick borne--Ornithodoros spp.
and DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the commercial availability of TYSABRI(R) (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.
ZUG, Switzerland & DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that they received approval from the European Commission to market TYSABRI(R) (natalizumab) as a treatment for relapsing remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses.
AVONEX is the most prescribed treatment for relapsing forms of multiple sclerosis worldwide (through November 2005), with more than 130,000 patients on therapy.
AVONEX, manufactured by Biogen Idec, was approved for relapsing forms of MS by the U.